1. Catalog
  2. Mastery of Obesity Care
Mastery of Obesity Care
Create Account
Availability
On-Demand
2 Courses
Cost
Member: $600.00
Non-Member: $675.00
Credit Offered
11 AMA PRA Category 1 Credits
11 ABIM MOC Points
The Mastery of Obesity Care Course is the second installment in a comprehensive, two-part educational series developed to advance the clinical skills of healthcare professionals treating obesity. Building upon the foundational principles introduced in the Foundations of Obesity Care—available as an on-demand course at obesityweek.org/foundations—this in-person program is designed for experienced clinicians, including physicians, nurse practitioners, physician associates, academics, and interprofessional care team members.

Held over two days in Atlanta, GA, November 3–4, 2025, the 12.5-hour CME course features an in-depth curriculum covering advanced pathophysiology of obesity, metabolic assessment, identification of adipose tissue disorders, and evidence-based pharmacologic, endoscopic, and surgical treatment strategies. The agenda includes sessions on nutrition science, genetics, and precision medicine, reflecting the latest advances in the field.

A highlight of the program is its applied, case-based learning component, where faculty lead participants through complex clinical scenarios involving sleep disorders, type 2 diabetes, MASLD (including MASH and liver transplantation considerations), cardiovascular disease, chronic kidney disease, cancer, psychiatric illness, and PCOS. These sessions promote clinical reasoning and real-world problem solving to enhance patient-centered care.

This course is a ticketed event at the 2025 ObesityWeek conference. All in-person course registrants will also receive on-demand recordings of the course at no additional fee. This course confers up to 12.5 CME credits that count toward ABIM MOC credits. This and all CME events produced by The Obesity Society count towards Group One credit when applying for the American Board of Obesity Medicine exam.
The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 11 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ACCME Activity ID 203331129
Date of Release: March 23, 2026
Date of Termination: December 31, 2028
No commercial support was received for this activity.
Agarwal, Monica, MD, MEHP, FACE, DABOM
- No Relevant Financial Relationships

Bartfield, Jessica, MD, DABOM
- No Relevant Financial Relationships

Burridge, Karli, PA-C, MMS, FOMA: - Advisor relationship with Boehringer Ingelheim and Novo Nordisk (Pharmaceuticals).
- Consultant relationship with Currax (Pharmaceuticals).
- Speaker relationship with Abbott (Medical Food), and Eli Lilly and Vivus (Pharmaceuticals).

George, Thomas, DNP, FNP-C, NASM-CPT, FOMA: - Consultant relationship with Epitomee Medical (Medical Device).
- Guest speaker, one time industry sponsored obesity symposium relationship with Currax (Pharmaceuticals).

Golden, Angela, DNP, FNP-C, FAANP, FOMA: - Advisor relationship with Boehringer Ingelheim, Currax, Eli Lilly, and Epitomee (Pharmaceuticals), and Weight Watchers (Medical Food).
- Consultant relationship with Novo Nordisk (Pharmaceuticals).
- Speaker relationship with Acella (Pharmaceuticals).

Horn, Deborah, DO, MPH: - Consultant relationship with Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Zealand (Pharmaceuticals).
- Researcher relationship with Eli Lilly and Novo Nordisk (Pharmaceuticals).
- Speaker relationship with Novo Nordisk (Pharmaceuticals).

Kaplan, Lee, MD, PhD, FTOS: - Consultant relationship with Altimmune, Amgen, AstraZeneca, Boehringer Ingelheim (Pharmaceuticals), Cytoki, Eli Lilly, Kallyope, Neurogastrx, Novo Nordisk, and Pfizer (Pharmaceuticals), and Johnson & Johnson, Oxford Medical Products, and Perspectum (Medical Device).

McConnell, Jeremy, MD, MFOMA: - Advisor relationship with Axsome and Eli Lilly (Pharmaceuticals), Fisher and Paykel, Nyxoah, and Zoll-Respicardia (Medical Device).
- Consultant relationship with Inspire Medical Systems, Inc (Medical Device).
- Speaker relationship with Avadel, Harmony Biosciences, Idorsia, and Novo Nordisk (Pharmaceuticals).

Rao, Aditi, MD
- No Relevant Financial Relationships

Ritten, Angela, DNP, APRN, FNP-BC: - Speaker relationship with Currax and Eli Lilly (Pharmaceuticals).

Simons-Linares, Roberto, MD: - Consultant relationship with 3D matrix, Boston Scientific, Medtronic, and Steris (Medical Device).

Tchang, Beverly, MD, DABOM: - Advisor relationship with Amgen, Boehringer-Ingelheim, Eli Lilly, Metsera, Novo Nordisk, Roche, Roman Health Ventures, Skye Bioscience, and Tern (Pharmaceuticals).
- Stock Options relationship with Roman Health Ventures (Pharmaceuticals).
Agarwal, Monica, MD, MEHP, FACE, DABOM: No Relevant Financial Relationships

Golden, Angela, DNP, FNP-C, FAANP, FOMA, FTOS: - Advisor relationship with Boehringer Ingelheim, Currax, Eli Lilly, and Epitomee (Pharmaceuticals), and Weight Watchers (Medical Food).
- Consultant relationship with Novo Nordisk (Pharmaceuticals).
- Speaker relationship with Acella (Pharmaceuticals).
No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.
1. Apovian cm, et al. J clin endocrinol metab. 2015;100(2):342-362.

2. Bays HE, et al. 2020. Https://obesitymedicine.Org/obesity-algorithm/ accessed February 12, 2020.

3. Garvey WT, et al. Endocr pract. 2016;22(suppl 3):1-203.

4. Wharton S, et al. Cmaj. 2020;192(31): e875-e891.

Melson, E., Miras, A. D., & Papamargaritis, D. (2023). Future therapies for obesity. Clinical medicine (London,: England), 23(4), 337–346. https://doi.org/10.7861/clinmed.2023-0144

6. Michael W Schwartz, Randy J Seeley, Lori M Zeltser, Adam Drewnowski, Eric Ravussin, Leanne M Redman, Rudolph L Leibel, Obesity Pathogenesis: An Endocrine Society Scientific Statement, Endocrine Reviews, Volume 38, Issue 4, 1 August 2017, Pages 267–296, https://doi.org/10.1210/er.2017-00111.

7. Bernard, M., Löbner, M., Lordick, F., Mehnert-Theuerkauf, A., Riedel-Heller, S. G., & Luck-Sikorski, C. (2022). Cancer prevention in females with and without obesity: Does perceived and internalised weight bias determine cancer prevention behaviour?. BMC women's health, 22(1), 511. https://doi.org/10.1186/s12905-022-02085-2
Powered By